Nilotinib

證據等級: L5

預測適應症: 1 個

Nilotinib: From Chronic Myelogenous Leukemia to Dermatofibrosarcoma Protuberans

One-Sentence Summary

Nilotinib is a second-generation BCR-ABL/KIT/PDGFRα/β tyrosine kinase inhibitor (TKI), originally developed and approved for Philadelphia chromosome-positive chronic myelogenous leukemia (CML). The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), with 0 clinical trials and 1 publication currently supporting this direction. The mechanistic rationale is strong — DFSP is driven by constitutive PDGFRβ activation, a known Nilotinib target — but formal clinical evidence remains absent.

Quick Overview

Item	Content
Original Indication	Philadelphia chromosome-positive chronic myelogenous leukemia (CML)
Predicted New Indication	Dermatofibrosarcoma Protuberans (DFSP)
TxGNN Prediction Score	99.31%
Evidence Level	L4 (Preclinical / mechanism studies only)
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor also active against KIT and PDGF receptors α and β. Compared to first-generation imatinib, it binds the kinase domain with greater affinity and can overcome several imatinib-resistance mutations. Its inhibitory potency against PDGFRβ is well established (IC₅₀ ≈ 20–50 nM in vitro).

DFSP is a rare soft-tissue sarcoma defined by a pathognomonic chromosomal translocation t(17;22)(q22;q13), which fuses the COL1A1 gene to PDGFB. The resulting fusion protein constitutively activates the PDGFRβ autocrine signalling loop, making PDGFRβ the central oncogenic driver of this tumour. This is the same target already exploited clinically by imatinib, which holds FDA approval for unresectable or metastatic DFSP. Because Nilotinib shares the PDGFRβ target with imatinib and demonstrates superior in-vitro potency, the TxGNN model’s high prediction score is mechanistically coherent and consistent with established oncology biology.

The theoretical advantage of Nilotinib over imatinib in DFSP is its potential utility after imatinib failure. However, no completed clinical trial has yet validated this hypothesis in DFSP patients, keeping the evidence at the preclinical/mechanism level (L4). The single available publication is a broad narrative review of PDGFR-inhibitor pharmacology and does not report patient outcomes specific to this indication.

Clinical Trial Evidence

Currently no related clinical trials registered for Nilotinib in Dermatofibrosarcoma Protuberans.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29408302	2018	Narrative Review	Pharmacological Research	Comprehensive review of small-molecule PDGFRα/β inhibitors in neoplastic disorders; discusses the PDGF signalling axis, receptor biology, and approved/investigational TKIs including Nilotinib; provides mechanistic rationale but no DFSP-specific clinical outcome data

India Market Information

Nilotinib currently holds no registered marketing authorizations in India. The drug is not commercially available through the local regulatory pathway and would require new drug application or special importation approval before clinical use.

Cytotoxicity

Nilotinib is an antineoplastic agent (targeted therapy — BCR-ABL/PDGFR tyrosine kinase inhibitor).

Item	Content
Cytotoxicity Classification	Targeted therapy (Second-generation BCR-ABL / KIT / PDGFRα/β TKI)
Myelosuppression Risk	Moderate — thrombocytopenia, neutropenia, and anaemia are reported class effects of BCR-ABL TKIs; CBC monitoring is essential
Emetogenicity Classification	Low to minimal
Monitoring Items	CBC with differential, liver function tests, serum lipase/amylase, electrolytes (QTc-relevant: potassium, magnesium), fasting glucose, ECG (QTc interval)
Handling Protection	Must follow cytotoxic drug handling regulations for oral targeted therapies

Safety Considerations

Drug Interactions (637 total interactions identified):

Major-level interactions requiring clinical attention:

Dexamethasone — Major (CYP3A4 inducer; may significantly reduce Nilotinib plasma levels)
Clarithromycin — Major (potent CYP3A4 inhibitor; may substantially increase Nilotinib exposure and QTc risk)
Picosulfuric acid — Major (electrolyte disturbance risk; additive QTc prolongation potential)
Polyethylene glycol 3350 with electrolytes — Major (electrolyte disturbance; QTc prolongation risk)

Representative moderate-level interactions:

Famotidine, Ranitidine, Rabeprazole, Omeprazole, Cimetidine (gastric pH-elevating agents reduce Nilotinib absorption), Hydrocortisone, Budesonide, Betamethasone, Triamcinolone (CYP3A4 effects), Pioglitazone, Saxagliptin (metabolic interactions), Bupropion, Aprepitant, Loperamide, Bisacodyl.

⚠️ Nilotinib carries known QTc prolongation risk. Co-administration with any QTc-prolonging agent or electrolyte-depleting preparation requires ECG monitoring and electrolyte correction before and during therapy.

For complete warnings and contraindications, please refer to the Tasigna® (Nilotinib) package insert, as formal safety label data was not included in this Evidence Pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic basis for Nilotinib in DFSP is scientifically sound — PDGFRβ is the confirmed oncogenic driver and Nilotinib is a potent PDGFRβ inhibitor — however, the current evidence consists of a single narrative review with no DFSP-specific clinical or preclinical experimental data. With zero registered clinical trials and no market authorization in India, the evidence base is insufficient to advance beyond a research hypothesis at this stage.

To proceed, the following is needed:

Preclinical data: In vitro PDGFRβ inhibition studies in DFSP cell lines; in vivo xenograft models to establish proof-of-concept before human trials
Comparative activity data: Head-to-head comparison with imatinib (the FDA-approved PDGFR inhibitor for DFSP) to quantify whether Nilotinib offers meaningful efficacy advantages
Safety label review: Obtain and parse the full Nilotinib prescribing information (Tasigna® SmPC / FDA label) to complete the safety profile, particularly QTc warnings and contraindications
Regulatory feasibility assessment: Determine whether a compassionate use / investigational new drug pathway exists in India for Nilotinib in DFSP, given zero local market authorization
Case report / retrospective series search: Systematic search for published case reports of Nilotinib use in DFSP (imatinib-refractory setting) to supplement the current evidence gap
Clinical trial registration: If preclinical data is supportive, design and register a Phase 1/2 single-arm trial in unresectable or imatinib-progressed DFSP
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.